在业绩停滞的档口，公司实控人被立案，玻尿酸三巨头之一的昊海生科正经历公司上市以来的关键拐点 时刻。 5月7日晚间，昊海生科收到控股股东、实际控制人之一蒋伟通知,其于近日收到中国证监会出具的《立 案告知书》，因涉嫌内幕交易被立案。不过公司方面同时指出，蒋伟被立案"与本公司股票无关"，并 且"不会对公司日常经营活动产生重大影响"。 源：公告 至于蒋伟参与了哪家上市公司的内幕交易不得而知，但可以确定的是蒋伟、游捷夫妇控制的昊海生科正 在面临业绩放缓的困境。 公开数据显示，2024年公司营业收入为27.0亿元，同比上升1.6%；净利润为4.2亿元，同比上升1.04%； 扣非净利润为3.79亿元，同比下降1.1%。和2023年相比无论是营收还是净利润的增速都在下滑，其中净 利润增长率更是从130.58%陡然降至1.04%。其中，公司业务中占比第二和第三的眼科产品与骨科产品 的营收因为受到新一轮的集采影响同比纷纷下滑。 | 产品线 | 2024年 | | 2023 年 | | 同比增长(%) | | --- | --- | --- | --- | --- | --- | | | 金额 | 占比(%) | 金额 | 占比( ...

Group 1 - Geely Auto proposed to privatize Zeekr with an offer of $2.57 per share, representing a 13.6% premium over the last trading price [1] - The offer also includes a premium of 20.0% over the volume-weighted average price of the last 30 trading days [1] - Geely currently holds approximately 65.7% of Zeekr's issued share capital [1] Group 2 - Sun Group announced the U.S. Department of Commerce has revoked its investigation into steel wheels made in Vietnam using Chinese components [2] - The revocation is expected to positively impact the company's export orders and future overseas business layout [2] Group 3 - Qingdao Beer plans to acquire 100% equity of Jimo Yellow Wine for a total consideration of RMB 665 million [3] - The acquisition aims to enhance industry synergy, competitiveness, and expand product lines and market channels [3] Group 4 - BeiGene reported a net loss of 94.503 million yuan in Q1 2025, a reduction in loss compared to the previous year [4] - The company achieved total revenue of 8.048 billion yuan, a year-on-year increase of 50.2%, driven by sales growth of its self-developed products [4] Group 5 - Daqin Railway reported a 0.99% year-on-year increase in cargo transportation volume for April [5] - Shaanxi Coal's self-produced coal sales reached 13.1033 million tons in April, up 0.76% year-on-year [5] Group 6 - Shennong Group sold 227,300 pigs in April, marking a 32.85% year-on-year increase [6] - Poly Developments reported a 25.44% year-on-year decrease in contracted sales amounting to 24.622 billion yuan in April [6] Group 7 - Hainan Development plans to acquire 51% equity of Wangying Technology [7] - Huafeng Measurement Control's shareholders plan to transfer 2.9% of shares at an initial price of 121.42 yuan per share [7] Group 8 - Various companies reported significant stock price fluctuations, with Changshan Pharmaceutical's injection not yet on the market and facing regulatory uncertainties [8] - The company is in the professional review stage for its diabetes treatment application [8]

Group 1 - The core issue involves the investigation of Jiang Wei, a major shareholder and actual controller of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading [1] - The investigation pertains solely to Jiang Wei as an individual and does not involve the company's stock or daily operations, indicating no significant impact on the company's regular business activities [2] Group 2 - On May 7, Haohai Biological Technology's stock closed at 53.17 yuan per share, down 0.21%, with a market capitalization of 12.4 billion yuan [3] - The company recently announced a stock buyback, having repurchased approximately 1.49 million A-shares, accounting for 0.64% of the total share capital, with a total transaction amount of about 85.94 million yuan [3] - For the fiscal year 2024, Haohai Biological Technology reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, a year-on-year increase of 1.04%, indicating stagnation in growth [3] - The overall gross margin decreased from 70.46% to 69.89%, despite the increasing revenue share from high-margin hyaluronic acid products, due to significant price declines in other products [3] Group 3 - In Q1 2025, Haohai Biological Technology reported total revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit attributable to shareholders of 90.31 million yuan, down 7.41% [4] - The decline in performance reflects intense competition in the hyaluronic acid and medical aesthetics market, with emerging alternative materials reshaping the landscape [4] - Research indicates that recombinant collagen may replicate the success of hyaluronic acid, supported by continuous improvements in supply chain policies and technological breakthroughs [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） * 僅供識別 证券代码：688366 证券简称：昊海生科 公告编号：2025-021 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於公司控股股東、實際控制人之一收到中國證券監督管理委員會立案告知書的公 告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年5月7日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執 行 ...

Group 1 - The core point of the news is that Haohai Biological Technology (688366.SH) announced that its controlling shareholder, Jiang Wei, is under investigation by the China Securities Regulatory Commission for insider trading, which is unrelated to the company's stock [1] - The investigation pertains solely to Jiang Wei as an individual and will not significantly impact the company's daily operations [1] - As of May 7, Haohai Biological's stock price was 53.17 yuan, with a market capitalization of 12.399 billion yuan [1] Group 2 - Haohai Biological is a technology innovation company focused on the research, production, and sales of medical devices and pharmaceuticals using biomedical materials and genetic engineering technology [3] - The company aims to provide innovative medical products through technological innovation and resource integration, gradually achieving import substitution in related pharmaceutical products [3] - As of 2023, Haohai Biological has completed industry restructuring in biomedical materials and has achieved leading advantages in four main business areas: ophthalmology, plastic surgery and wound care, orthopedics, and anti-adhesion and hemostasis [3] Group 3 - For Q1 2025, Haohai Biological reported a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit attributable to shareholders of 90.3121 million yuan, down 7.41% year-on-year [3] - The company's basic earnings per share for the first quarter were 0.39 yuan [3] - As of May 7, the stock price of Haohai Biological had decreased by 0.21% [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於召開2024年度暨2025年第一季度中英雙語業績說明會的公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年5月6日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執 行董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：68836 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於第二期以集中競價交易方式回購公司A股股份的進展公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年5月6日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執行 董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：688366 证券简 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company reported a total revenue of 621 million yuan in Q1 2025, a decrease of 4.44% year-on-year, with a net profit attributable to the parent company of 90 million yuan, down 7.41% [1]. - The ophthalmology business faced challenges due to price declines from centralized procurement, while the medical aesthetics sector continued to experience weak terminal consumption [2]. - The company is focused on R&D and innovation, with new products steadily advancing, including approvals for new intraocular lenses and the launch of the fourth-generation hyaluronic acid product "Hai Mei Yue Bai" [2]. - The gross profit margin slightly improved to 69.52% in Q1 2025, attributed to an increase in the proportion of high-margin medical aesthetics products [3]. - The company expects revenue growth to reach 3.103 billion yuan in 2025, with net profit projected at 489 million yuan, reflecting a compound annual growth rate of 16.42% from 2024 to 2025 [4][5]. Summary by Sections Financial Performance - In Q1 2025, the company achieved a gross profit margin of 69.52%, with a net profit margin of 14.60% [3]. - The company reported a stable expense ratio of 51.79%, with sales expenses increasing slightly to 31.35% [3]. - The operating cash flow for Q1 2025 was 86 million yuan, indicating healthy cash flow management [3]. Product Development - The company is advancing its product pipeline, including new medical aesthetics products and intraocular lenses, which are expected to enhance market share [2]. - The innovative "Hai Mei Yue Bai" product is anticipated to address long-standing consumer issues related to hyaluronic acid retention [2]. Market Outlook - The report forecasts revenue growth for the company from 3.103 billion yuan in 2025 to 3.934 billion yuan in 2027, with a corresponding increase in net profit [4][5]. - The company is positioned to benefit from a recovery in the ophthalmology sector as product pipelines expand and centralized procurement impacts stabilize [4].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | H 股 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...